Practo founder, former Lenskart and Ola executives raise $5 million from South Park Commons for healthcare startup Cent

Cent founders Shashank ND (M), Anshul Khandelwal (L) and Arpit Garg (R)

Shashank ND, founder and chief executive of Practo, along with Arpit Garg, former head of product at Lenskart, and Anshul Khandelwal, former marketing chief and product lead at Ola Electric have raised about $5 million in seed funding for their preventive healthcare startup, Cent, from South Park Commons and family office OneFlow Holdings, according to people familiar with the matter.

OneFlow Holdings is the family office of Practo's Shashank ND.

The company announced the launch of Cent on March 6, positioning it as an AI-led platform focused on early detection of cancer, cardiac, neurological and metabolic risks in individuals before symptoms appear.

'Cent' is the short for Century, where the company aims to make people live until they are 100 years old.

The Bengaluru-based startup combines advanced imaging with more than 120 biomarkers and AI-driven analysis to screen for over 300 health conditions in a single visit.

Founded in 2025, the company said it has been operational since the first quarter of FY26 and has completed more than 1,500 scans so far. According to Cent, 26 percent of these scans revealed clinically meaningful findings, while 4 percent identified critical conditions requiring immediate medical attention, largely among individuals who were asymptomatic at the time.

“India has built world-class treatment capability, but our healthcare system is still oriented around disease that has already declared itself. In the preventive space, we need dedicated infrastructure, the right technology, the right protocols, the right capital, built specifically for detection. That is the gap Cent is designed to close,” said Shashank ND, founder and chair, Cent.

Cent’s screening model is built around a proprietary protocol called CCNM (Cardiac, Cancer, Neurological and Metabolic), which integrates whole-body MRI, low-dose CT, DEXA scans, ECG, and blood and urine biomarkers, along with AI-driven synthesis to generate organ-level risk assessments followed by clinical consultation.

“Five years ago, this level of integrated screening was not technically feasible. The convergence of advanced MRI, AI-assisted radiology, and multi-omics analysis now allows us to screen for 300+ conditions in a single visit and a faster scan time,” said Arpit Garg, co-founder and chief AI and research officer at Cent.

The company said it is currently growing 50 percent month-on-month and has reached an annualised revenue run rate of around $2 million. It aims to complete 50,000 scans this year as it expands capacity.

Cent is also building a network of single-purpose detection centres, with the first facilities expected to roll out beginning April 2026 across Mumbai, Delhi and Bengaluru, followed by expansion into Pune and Hyderabad.

“The bottleneck in early detection has never been intent; it has been the operating model. If you depend on symptom-led referrals and multi-purpose centres, you can’t scale rigour. By designing around one protocol and one workflow, we can drive utilisation, consistency and cost discipline,” said Anshul Khandelwal, co-founder and chief business officer at Cent.

The company did not comment on the deal size.

Cent said its long-term ambition is to enable 10 million scans and contribute to one million lives saved by 2035, as it looks to make early detection a more mainstream part of healthcare in India.